{"id":389628,"date":"2020-11-30T09:18:31","date_gmt":"2020-11-30T14:18:31","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=389628"},"modified":"2020-11-30T09:18:31","modified_gmt":"2020-11-30T14:18:31","slug":"iterum-therapeutics-submits-new-drug-application-to-u-s-food-and-drug-administration-for-oral-sulopenem","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/iterum-therapeutics-submits-new-drug-application-to-u-s-food-and-drug-administration-for-oral-sulopenem\/","title":{"rendered":"Iterum Therapeutics Submits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem"},"content":{"rendered":"
\n

\n —<\/em>
\n F<\/em>
\n irst <\/em>
\n O<\/em>
\n ral <\/em>
\n Penem <\/em>
\n in the U<\/em>
\n .<\/em>
\n S<\/em>
\n .<\/em>
\n and <\/em>
\n First New Oral Treatment <\/em>
\n for uUTI<\/em>
\n s<\/em>
\n in <\/em>
\n Over <\/em>
\n 20 <\/em>
\n Years<\/em>
\n , if approved<\/em>
\n –<\/em>
\n –<\/em>
\n \n <\/p>\n

\n –<\/em>
\n –<\/em>
\n Potential <\/em>
\n Approval Q3 2021<\/em>
\n with Priority Review<\/em>
\n —<\/em>\n <\/p>\n

DUBLIN, Ireland and CHICAGO, Nov. 30, 2020 (GLOBE NEWSWIRE) — Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that it has submitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for sulopenem etzadroxil\/probenecid (oral sulopenem) for the treatment of uncomplicated urinary tract infections (uUTIs) in patients with a quinolone non-susceptible pathogen.<\/p>\n

\u201cThe submission of the NDA filing for oral sulopenem is a significant step forward in bringing new antibiotics to patients to help address the challenge of antibiotic resistance,\u201d said Corey Fishman, Chief Executive Officer. \u201cOral sulopenem, if approved, would mean that physicians and patients have the opportunity to benefit from the proven efficacy and safety of penem antibiotics that, to date in the U.S., have only been available in IV formulations. We are now one step closer to realizing the goal of bringing this much needed medicine to the over six million patients with cipro-resistant UTIs each year in the U.S.\u201d<\/p>\n

The NDA submission includes data from the SURE-1, SURE-2 and SURE-3 phase 3 clinical trials, in which oral sulopenem was well tolerated with no significant drug related adverse events. The SURE-1 clinical trial (uUTIs) demonstrated statistical superiority of oral sulopenem to the widely used comparator, ciprofloxacin, for the primary efficacy endpoint of clinical and microbiologic response at the test-of-cure visit for patients with a quinolone non-susceptible pathogen.<\/p>\n

\n About Iterum Therapeutics plc<\/strong>\n <\/p>\n

Iterum Therapeutics plc is a clinical-stage pharmaceutical company dedicated to developing differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. Iterum Therapeutics is advancing its first compound, sulopenem, a novel penem anti-infective compound, in Phase 3 clinical development with an oral formulation and IV formulation. Sulopenem has demonstrated potent in vitro<\/em> activity against a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics. Iterum Therapeutics has received Qualified Infectious Disease Product (QIDP) and Fast Track designations for its oral and IV formulations of sulopenem in seven indications.<\/p>\n

\n Forward-Looking Statements<\/strong>\n <\/p>\n

This press release contains forward-looking statements. These forward-looking statements include, without limitation, statements regarding, among other things, timing of the review of regulatory filings and the market opportunity for, and potential market acceptance of, oral sulopenem for uUTIs, and the Company\u2019s plans, strategies and prospects for its business. In some cases, forward-looking statements can be identified by words such as \u201cmay,\u201d \u201cbelieves,\u201d \u201cintends,\u201d \u201cseeks,\u201d \u201canticipates,\u201d \u201cplans,\u201d \u201cestimates,\u201d \u201cexpects,\u201d \u201cshould,\u201d \u201cassumes,\u201d \u201ccontinues,\u201d \u201ccould,\u201d \u201cwould,\u201d \u201cwill,\u201d \u201cfuture,\u201d \u201cpotential\u201d or the negative of these or similar terms and phrases. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company\u2019s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements include all matters that are not historical facts. Actual future results may be materially different from what is expected due to factors largely outside the Company\u2019s control, including the uncertainties inherent in the initiation and conduct of clinical trials, availability and timing of data from clinical trials, changes in regulatory requirements or decisions of regulatory authorities, the timing of approval of any submission, changes in public policy or legislation, commercialization plans and timelines, if oral sulopenem is approved, the actions of third-party clinical research organizations, suppliers and manufacturers, the accuracy of the Company\u2019s expectations regarding how far into the future the Company\u2019s cash on hand will fund the Company\u2019s ongoing operations, the sufficiency of the Company\u2019s cash resources and the Company\u2019s ability to continue as a going concern, the impact of COVID-19 and related responsive measures thereto, the Company\u2019s ability to maintain listing on the Nasdaq Stock Market, risks and uncertainties concerning the outcome, impact, effects and results of the Company\u2019s evaluation of corporate, organizational, strategic, financial and financing alternatives, including the terms, timing, structure, value, benefits and costs of any corporate, organizational, strategic, financial or financing alternative and the Company\u2019s ability to complete one at all, the price of the Company\u2019s securities and other factors discussed under the caption \u201cRisk Factors\u201d in its most recently filed Quarterly Report on Form 10-Q, and other documents filed with the SEC from time to time. Forward-looking statements represent the Company\u2019s beliefs and assumptions only as of the date of this press release. Except as required by law, the Company assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.<\/p>\n

\n Investor Contact:<\/strong>
\n
Judy Matthews
Chief Financial Officer
312-778-6073
IR@iterumtx.com<\/a><\/u><\/p>\n<\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

— F irst O ral Penem in the U . S . and First New Oral Treatment for uUTI s in Over 20 Years , if approved – – – – Potential Approval Q3 2021 with Priority Review — DUBLIN, Ireland and CHICAGO, Nov. 30, 2020 (GLOBE NEWSWIRE) — Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that it has submitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for sulopenem etzadroxil\/probenecid (oral sulopenem) for the treatment of uncomplicated urinary tract infections (uUTIs) in patients with a … <\/p>\n

Continue reading “Iterum Therapeutics Submits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-389628","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nIterum Therapeutics Submits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/iterum-therapeutics-submits-new-drug-application-to-u-s-food-and-drug-administration-for-oral-sulopenem\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Iterum Therapeutics Submits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"— F irst O ral Penem in the U . S . and First New Oral Treatment for uUTI s in Over 20 Years , if approved – – – – Potential Approval Q3 2021 with Priority Review — DUBLIN, Ireland and CHICAGO, Nov. 30, 2020 (GLOBE NEWSWIRE) — Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that it has submitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for sulopenem etzadroxil\/probenecid (oral sulopenem) for the treatment of uncomplicated urinary tract infections (uUTIs) in patients with a … Continue reading "Iterum Therapeutics Submits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/iterum-therapeutics-submits-new-drug-application-to-u-s-food-and-drug-administration-for-oral-sulopenem\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-30T14:18:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MjUzOCMzODQ0ODA2IzIxMjA2NzM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iterum-therapeutics-submits-new-drug-application-to-u-s-food-and-drug-administration-for-oral-sulopenem\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iterum-therapeutics-submits-new-drug-application-to-u-s-food-and-drug-administration-for-oral-sulopenem\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Iterum Therapeutics Submits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem\",\"datePublished\":\"2020-11-30T14:18:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iterum-therapeutics-submits-new-drug-application-to-u-s-food-and-drug-administration-for-oral-sulopenem\\\/\"},\"wordCount\":860,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iterum-therapeutics-submits-new-drug-application-to-u-s-food-and-drug-administration-for-oral-sulopenem\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MjUzOCMzODQ0ODA2IzIxMjA2NzM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iterum-therapeutics-submits-new-drug-application-to-u-s-food-and-drug-administration-for-oral-sulopenem\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iterum-therapeutics-submits-new-drug-application-to-u-s-food-and-drug-administration-for-oral-sulopenem\\\/\",\"name\":\"Iterum Therapeutics Submits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iterum-therapeutics-submits-new-drug-application-to-u-s-food-and-drug-administration-for-oral-sulopenem\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iterum-therapeutics-submits-new-drug-application-to-u-s-food-and-drug-administration-for-oral-sulopenem\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MjUzOCMzODQ0ODA2IzIxMjA2NzM=\",\"datePublished\":\"2020-11-30T14:18:31+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iterum-therapeutics-submits-new-drug-application-to-u-s-food-and-drug-administration-for-oral-sulopenem\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iterum-therapeutics-submits-new-drug-application-to-u-s-food-and-drug-administration-for-oral-sulopenem\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iterum-therapeutics-submits-new-drug-application-to-u-s-food-and-drug-administration-for-oral-sulopenem\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MjUzOCMzODQ0ODA2IzIxMjA2NzM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MjUzOCMzODQ0ODA2IzIxMjA2NzM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iterum-therapeutics-submits-new-drug-application-to-u-s-food-and-drug-administration-for-oral-sulopenem\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Iterum Therapeutics Submits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Iterum Therapeutics Submits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/iterum-therapeutics-submits-new-drug-application-to-u-s-food-and-drug-administration-for-oral-sulopenem\/","og_locale":"en_US","og_type":"article","og_title":"Iterum Therapeutics Submits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem - Market Newsdesk","og_description":"— F irst O ral Penem in the U . S . and First New Oral Treatment for uUTI s in Over 20 Years , if approved – – – – Potential Approval Q3 2021 with Priority Review — DUBLIN, Ireland and CHICAGO, Nov. 30, 2020 (GLOBE NEWSWIRE) — Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that it has submitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for sulopenem etzadroxil\/probenecid (oral sulopenem) for the treatment of uncomplicated urinary tract infections (uUTIs) in patients with a … Continue reading \"Iterum Therapeutics Submits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/iterum-therapeutics-submits-new-drug-application-to-u-s-food-and-drug-administration-for-oral-sulopenem\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-30T14:18:31+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MjUzOCMzODQ0ODA2IzIxMjA2NzM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iterum-therapeutics-submits-new-drug-application-to-u-s-food-and-drug-administration-for-oral-sulopenem\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iterum-therapeutics-submits-new-drug-application-to-u-s-food-and-drug-administration-for-oral-sulopenem\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Iterum Therapeutics Submits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem","datePublished":"2020-11-30T14:18:31+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iterum-therapeutics-submits-new-drug-application-to-u-s-food-and-drug-administration-for-oral-sulopenem\/"},"wordCount":860,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iterum-therapeutics-submits-new-drug-application-to-u-s-food-and-drug-administration-for-oral-sulopenem\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MjUzOCMzODQ0ODA2IzIxMjA2NzM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iterum-therapeutics-submits-new-drug-application-to-u-s-food-and-drug-administration-for-oral-sulopenem\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/iterum-therapeutics-submits-new-drug-application-to-u-s-food-and-drug-administration-for-oral-sulopenem\/","name":"Iterum Therapeutics Submits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iterum-therapeutics-submits-new-drug-application-to-u-s-food-and-drug-administration-for-oral-sulopenem\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iterum-therapeutics-submits-new-drug-application-to-u-s-food-and-drug-administration-for-oral-sulopenem\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MjUzOCMzODQ0ODA2IzIxMjA2NzM=","datePublished":"2020-11-30T14:18:31+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iterum-therapeutics-submits-new-drug-application-to-u-s-food-and-drug-administration-for-oral-sulopenem\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/iterum-therapeutics-submits-new-drug-application-to-u-s-food-and-drug-administration-for-oral-sulopenem\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iterum-therapeutics-submits-new-drug-application-to-u-s-food-and-drug-administration-for-oral-sulopenem\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MjUzOCMzODQ0ODA2IzIxMjA2NzM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MjUzOCMzODQ0ODA2IzIxMjA2NzM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iterum-therapeutics-submits-new-drug-application-to-u-s-food-and-drug-administration-for-oral-sulopenem\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Iterum Therapeutics Submits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/389628","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=389628"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/389628\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=389628"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=389628"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=389628"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}